CVC  Sanofi Ventures

http://www.sanofiventures.com/





     Office Locations:

50 Binney Street
Cambridge, MA 02142
Phone: 617-252-7500
Fax: 617-252-7600

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Sanofi Ventures is the corporate venture capital arm of Sanofi. Previously known as Sanofi-Genzyme BioVentures, the firm offers its portfolio companies access to Sanofi's established expertise and capabilities in science, preclinical and clinical development, regulatory, manufacturing, market access, commercialization, and more. Sanofi invests in early-stage companies developing transformative technologies and products that are considered too early for business development. Sanofi Ventures invests directly in private early-stage biotech and digital health companies with transformative new products and technologies that align with Sanofi's strategy. Current core areas of strategic interest include: rare diseases; vaccines; breakthrough therapies in other core areas of interest: immunology, neurology, oncology, diabetes, and cardio vascular disease; and digital health.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Bernard Davitian VP, Managing Director
    Christopher Gagliardi Director of Investments
    Jason Hafler Senior Director of Investments
    Ruchita Sinha Sr. Director of Investments and Principal

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      11/13/2018


      Kymera Therapeutics


      MA


      $65,000,000


      Series B


      08/01/2018


      Evidation Health


      CA


      $30,000,000


      Series C


     

    Portfolio companies include:


      Common Sensing
        web link


      Curisium
        web link


      Edimer Pharmaceuticals
        web link


      Esperance Pharmaceuticals
        web link


      Evidation Health
        web link


      Expansion Therapeutics
        web link


      Fate Therapeutics
        web link


      GlycoMimetics
        web link


      Immune Design
        web link


      ImmuneXcite
        web link


      Inozyme Pharma


      Kahr Medical
        web link


      Kymera Therapeutics
        web link


      LTI
        web link


      Navitor Pharmaceuticals
        web link


      NeuroVia


      Omada Health
        web link


      Ovid Therapeutics
        web link


      Proteostasis Therapeutics
        web link


      Science 37
        web link


      Selecta
        web link


      Ultragenyx
        web link


      Valerion Therapeutics
        web link


      Yumanity Therapeutics
        web link


     

    Recent News: